Mutual of America Capital Management LLC Sells 187 Shares of Insulet Co. (NASDAQ:PODD)

Mutual of America Capital Management LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,378 shares of the medical instruments supplier’s stock after selling 187 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Insulet were worth $1,779,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its stake in Insulet by 119.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after purchasing an additional 43,147 shares during the period. Orion Portfolio Solutions LLC boosted its stake in Insulet by 276.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock valued at $2,069,000 after purchasing an additional 7,507 shares during the period. Asset Management One Co. Ltd. boosted its stake in Insulet by 33.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after purchasing an additional 9,240 shares during the period. Aquila Investment Management LLC bought a new stake in Insulet during the 4th quarter valued at approximately $1,302,000. Finally, Allianz Asset Management GmbH boosted its stake in Insulet by 85.1% during the 4th quarter. Allianz Asset Management GmbH now owns 108,109 shares of the medical instruments supplier’s stock valued at $23,457,000 after purchasing an additional 49,715 shares during the period.

Analysts Set New Price Targets

Several brokerages recently weighed in on PODD. Redburn Atlantic began coverage on Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 target price for the company. Barclays cut their price target on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Raymond James cut their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Jefferies Financial Group upped their price target on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a report on Tuesday, May 7th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average price target of $239.18.

Insulet Trading Down 0.8 %

PODD stock opened at $201.98 on Monday. The business has a fifty day moving average price of $189.42 and a 200 day moving average price of $185.23. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $293.64. The stock has a market capitalization of $14.15 billion, a price-to-earnings ratio of 61.21, a P/E/G ratio of 3.64 and a beta of 1.16. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. During the same period last year, the firm posted $0.23 EPS. The business’s revenue was up 23.3% on a year-over-year basis. Analysts expect that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy J. Scannell sold 7,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the completion of the sale, the director now directly owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Insulet news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the transaction, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the completion of the transaction, the director now owns 35,586 shares in the company, valued at $6,779,488.86. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock valued at $2,636,286 in the last three months. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.